Homologous recombination deficiency and immunotherapy response in microsatellite-stable colorectal cancer: Evidence from a cohort study in China

Figure 2 Homologous recombination deficiency-related gene alterations and homologous recombination deficiency-score distribution among colorectal cancer patients. A: Each bar represents the number of patients carrying alterations in homologous recombination deficiency (HRD)-related genes, including germline and somatic alterations, with 52 individuals carrying the relevant alterations; B: Each bar represents the number of alterations in one HRD-related gene in the total population, including germline and somatic alterations; C: The X-axis, Y-axis, and Z-axis represent the telomere-allele imbalance, loss of heterozygosity, and large-scale state transition scores, respectively. The blue dots represent colorectal cancer patients whose sum of the three is greater than or equal to 30. HRD: Homologous recombination deficiency; LOH: Loss of heterozygosity; LST: Large-scale state transition.